{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T09:56:38Z","timestamp":1738749398974,"version":"3.37.0"},"reference-count":10,"publisher":"Walter de Gruyter GmbH","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,25]]},"abstract":"Abstract<\/jats:title>\n \n Objectives<\/jats:title>\n Hypothalamic hamartoma (HH) is a rare condition that causes epilepsy and central precocious puberty (CPP) at an early age. In this report, we describe a child with CPP secondary to HH and discuss the current literature.<\/jats:p>\n <\/jats:sec>\n \n Case presentation<\/jats:title>\n A 26-month-old girl was brought to our hospital for evaluation of breast enlargement. Her parents were first-degree relatives. Her breast development was categorized as Tanner stage 3, and her bone age was 7 years\/4\u00a0months. Laboratory investigations were consistent with CPP. Brain magnetic resonance imaging (MRI) revealed a smooth, spherical lesion in the hypothalamus, located in the\u00a0tuber cinereum and measuring 11\u00a0\u00d7\u00a09\u00a0\u00d7\u00a010\u202fmm. The lesion\u00a0was identified as a HH. The patient was started on gonadotropin-releasing hormone analogue therapy, specifically 200\u202f\u03bcg\/kg\/month of leuprolide acetate (3.75\u202fmg depot) administered intramuscularly every 28\u00a0days. During the 2-year follow-up, her breast development remained at Tanner stage 3, and she did not develop axillary or pubic hair. Her bone age was 7 years\/6\u00a0months (chronological age; 4 years\/2\u00a0months). 2-year follow-up MRI showed no change in the size or contours of the HH compared with the initial diagnosis. No side effects from the medical treatment were observed during the follow-up period.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n In patients under the age of 4 years showing signs of CPP, HH should be considered as diagnosis. All patients receiving medical treatment should be closely monitored.<\/jats:p>\n <\/jats:sec>","DOI":"10.1515\/jpem-2024-0273","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T02:40:41Z","timestamp":1734921641000},"page":"187-190","source":"Crossref","is-referenced-by-count":0,"title":["Central precocious puberty in a toddler with hypothalamic hamartoma"],"prefix":"10.1515","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8474-6835","authenticated-orcid":false,"given":"Banu","family":"Turhan","sequence":"first","affiliation":[{"name":"Pediatric Endocrinology Clinic , Bilkent City Hospital , Ankara , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7888-7295","authenticated-orcid":false,"given":"G\u00f6n\u00fcl","family":"B\u00fcy\u00fcky\u0131lmaz","sequence":"additional","affiliation":[{"name":"Pediatric Endocrinology Clinic , Bilkent City Hospital , Ankara , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-9128","authenticated-orcid":false,"given":"Mehmet","family":"Boyraz","sequence":"additional","affiliation":[{"name":"Pediatric Endocrinology Clinic , Bilkent City Hospital , Ankara , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2024,12,24]]},"reference":[{"key":"2025020411462943208_j_jpem-2024-0273_ref_001","doi-asserted-by":"crossref","unstructured":"Latronico, AC, Brito, VN, Carel, JC. Causes, diagnosis, and treatment of central precocious puberty. Lancet Diabetes Endocrinol 2016;4:265\u201374. https:\/\/doi.org\/10.1016\/S2213-8587(15)00380-0.","DOI":"10.1016\/S2213-8587(15)00380-0"},{"key":"2025020411462943208_j_jpem-2024-0273_ref_002","doi-asserted-by":"crossref","unstructured":"Greiner, H, Leach, JL, Lee, KH, Krueger, DA. Anti-NMDA receptor encephalitis presenting with imaging findings and clinical features mimicking rasmussen syndrome. Seizure 2011;20:266\u201370. https:\/\/doi.org\/10.1016\/j.seizure.2010.11.013.","DOI":"10.1016\/j.seizure.2010.11.013"},{"key":"2025020411462943208_j_jpem-2024-0273_ref_003","doi-asserted-by":"crossref","unstructured":"Suh, J, Choi, Y, Oh, JS, Song, K, Choi, HS, Kwon, A, et al.. Management of central precocious puberty in children with hypothalamic hamartoma. Children 2021;8:711. https:\/\/doi.org\/10.3390\/children8080711.","DOI":"10.3390\/children8080711"},{"key":"2025020411462943208_j_jpem-2024-0273_ref_004","unstructured":"Freeman, JL, Coleman, LT, Wellard, RM, Kean, MJ, Rosenfeld, JV, Jackson, GD, et al.. MR imaging and spectroscopic study of epileptogenic hypothalamic hamartomas: analysis of 72 cases. AJNR Am J Neuroradiol 2004;25:450\u201362."},{"key":"2025020411462943208_j_jpem-2024-0273_ref_005","doi-asserted-by":"crossref","unstructured":"Ng, YT, Rekate, HL, Prenger, EC, Chung, SS, Feiz-Erfan, I, Wang, NC, et al.. Transcallosal resection of hypothalamic hamartoma for intractable epilepsy. Epilepsia 2006;47:1192\u2013202. https:\/\/doi.org\/10.1111\/j.1528-1167.2006.00516.x.","DOI":"10.1111\/j.1528-1167.2006.00516.x"},{"key":"2025020411462943208_j_jpem-2024-0273_ref_006","doi-asserted-by":"crossref","unstructured":"Bernal, B, Grossman, S, Gonzalez, R, Altman, N. FMRI under sedation: what is the best choice in children? J Clin Med Res 2012;4:363\u201370. https:\/\/doi.org\/10.4021\/jocmr1047w.","DOI":"10.4021\/jocmr1047w"},{"key":"2025020411462943208_j_jpem-2024-0273_ref_007","doi-asserted-by":"crossref","unstructured":"Corbet, BG, Liang, H, Lancaster, R, Cross, JH, Tisdall, M, Varadkar, S, et al.. Neuropsychiatric profile of paediatric hypothalamic hamartoma: systematic review and case series. Dev Med Child Neurol 2019;61:1377\u201385. https:\/\/doi.org\/10.1111\/dmcn.14241.","DOI":"10.1111\/dmcn.14241"},{"key":"2025020411462943208_j_jpem-2024-0273_ref_008","doi-asserted-by":"crossref","unstructured":"Neville, KA, Walker, JL. Precocious pubarche is associated with SGA, prematurity, weight gain, and obesity. Arch Dis Child 2005;90:258\u201361. https:\/\/doi.org\/10.1136\/adc.2004.053959.","DOI":"10.1136\/adc.2004.053959"},{"key":"2025020411462943208_j_jpem-2024-0273_ref_009","doi-asserted-by":"crossref","unstructured":"Brito, PC, Lopes, V, Antunes, E, Alves, M, Gon\u00e7alves, I, Matos, AC. Hypoglycemia in a non-diabetic patient and the side effects of diazoxide use. Cureus 2023;15:e36804. https:\/\/doi.org\/10.7759\/cureus.36804.","DOI":"10.7759\/cureus.36804"},{"key":"2025020411462943208_j_jpem-2024-0273_ref_010","doi-asserted-by":"crossref","unstructured":"Guaraldi, F, Beccuti, G, Gori, D, Ghizzoni, L. Management of endocrine disease: long-term outcomes of the treatment of central precocious puberty. Eur J Endocrinol 2016;174:R79\u201387. https:\/\/doi.org\/10.1530\/EJE-15-0590.","DOI":"10.1530\/EJE-15-0590"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2024-0273\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2024-0273\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T11:46:47Z","timestamp":1738669607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2024-0273\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,24]]},"references-count":10,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,12,17]]},"published-print":{"date-parts":[[2025,2,25]]}},"alternative-id":["10.1515\/jpem-2024-0273"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2024-0273","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"type":"print","value":"0334-018X"},{"type":"electronic","value":"2191-0251"}],"subject":[],"published":{"date-parts":[[2024,12,24]]}}}